Readystate Asset Management LP bought a new stake in RxSight, Inc. (NASDAQ:RXST – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 18,060 shares of the company’s stock, valued at approximately $728,000. Readystate Asset Management LP owned approximately 0.05% of RxSight as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in the company. Artisan Partners Limited Partnership grew its position in shares of RxSight by 17.3% during the third quarter. Artisan Partners Limited Partnership now owns 2,437,765 shares of the company’s stock worth $67,989,000 after acquiring an additional 359,295 shares during the last quarter. BlackRock Inc. grew its position in shares of RxSight by 30.6% during the second quarter. BlackRock Inc. now owns 1,629,928 shares of the company’s stock worth $46,942,000 after acquiring an additional 382,119 shares during the last quarter. Lord Abbett & CO. LLC grew its position in shares of RxSight by 13.8% during the third quarter. Lord Abbett & CO. LLC now owns 1,628,320 shares of the company’s stock worth $45,414,000 after acquiring an additional 197,099 shares during the last quarter. Vanguard Group Inc. grew its position in shares of RxSight by 3.5% during the fourth quarter. Vanguard Group Inc. now owns 1,484,010 shares of the company’s stock worth $59,835,000 after acquiring an additional 50,057 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its position in shares of RxSight by 61.2% during the fourth quarter. Nuveen Asset Management LLC now owns 695,705 shares of the company’s stock worth $28,051,000 after acquiring an additional 264,228 shares during the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.
Insider Buying and Selling at RxSight
In other news, CFO Shelley B. Thunen sold 20,000 shares of RxSight stock in a transaction on Monday, April 1st. The stock was sold at an average price of $49.90, for a total transaction of $998,000.00. Following the completion of the transaction, the chief financial officer now owns 8,402 shares of the company’s stock, valued at approximately $419,259.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Shelley B. Thunen sold 20,000 shares of RxSight stock in a transaction on Monday, April 1st. The stock was sold at an average price of $49.90, for a total transaction of $998,000.00. Following the completion of the transaction, the chief financial officer now owns 8,402 shares of the company’s stock, valued at approximately $419,259.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Shelley B. Thunen sold 10,000 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $56.37, for a total transaction of $563,700.00. Following the completion of the transaction, the chief financial officer now directly owns 13,691 shares of the company’s stock, valued at approximately $771,761.67. The disclosure for this sale can be found here. Over the last quarter, insiders sold 141,641 shares of company stock valued at $6,988,022. 21.13% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on RxSight
RxSight Stock Performance
RxSight stock traded down $1.08 during midday trading on Thursday, reaching $51.75. The company’s stock had a trading volume of 397,195 shares, compared to its average volume of 437,776. RxSight, Inc. has a fifty-two week low of $17.00 and a fifty-two week high of $58.21. The stock’s 50 day simple moving average is $52.50 and its 200 day simple moving average is $40.62. The firm has a market capitalization of $1.91 billion, a PE ratio of -36.19 and a beta of 1.22.
RxSight (NASDAQ:RXST – Get Free Report) last released its earnings results on Wednesday, February 28th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.10. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. The company had revenue of $28.58 million during the quarter, compared to the consensus estimate of $28.60 million. Equities analysts predict that RxSight, Inc. will post -0.94 earnings per share for the current year.
About RxSight
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Read More
- Five stocks we like better than RxSight
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Comprehensive PepsiCo Stock Analysis
- When to Sell a Stock for Profit or Loss
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What Are Dividend Champions? How to Invest in the Champions
- Bear Market Funds to Watch This Year
Want to see what other hedge funds are holding RXST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RxSight, Inc. (NASDAQ:RXST – Free Report).
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.